Effects of icariin on asthma mouse model are associated with regulation of prostaglandin D2 level.

J Qiao,S Sun,L Yuan,J Wang
DOI: https://doi.org/10.1016/j.aller.2017.02.007
2017-01-01
Allergologia et Immunopathologia
Abstract:Background: We aimed to observe the effect of icariin on an asthma mouse model and explore the potential underlying mechanisms. Methods: The asthma mouse model was established by ovalbunnin (OVA) sensitisation and respiratory syncytial virus (RSV) infection and then treated with icariin. Airway resistance was assessed by whole body plethysmograph. In addition, pathological slides were stained with haematoxylin-eosin, and the peribronchial inflammation was observed microscopically. The concentration of prostaglandin D2 (PGD2) in serum and bronchoalveolar lavage fluid (BALF) was detected by enzyme-linked innmuno sorbent assay (ELISA). The relative level of prostaglandin D2 receptor 2 (CRTH2) mRNA was assessed by real-time quantitative PCR. Results: Compared with the icariin-untreated group, there was a significant reduction of Penh in the treated group. Total leucocyte amount and all sorts of leukocytes were lower in the treated group than in the untreated group. HE staining results revealed that a large number of inflammatory cells infiltrated into the peribronchial tissues of untreated group, and the degree of airway inflammation decreased significantly in the treated group. PGD2 in serum and BALF, as well as CRTH2 mRNA level in lung tissues were lower id the treated group than in the untreated group. Conclusion: Icariin is a promising therapeutic strategy for asthma, and PGD2 might be a new target for asthma therapy in OVA-induced and RSV-infected asthma model. (C) 2017 SEICAP. Published by Elsevier Espana, S.L.U. All rights reserved.
What problem does this paper attempt to address?